Anavex Life Sciences Corp. — FY2020 Form 10-K
Reporting period: Fiscal year ended September 30, 2020. This is an annual report, not a standalone fourth-quarter filing. Anavex is a clinical-stage biotechnology company developing CNS therapies; it reported no operating revenue and has no marketed products.
Business context and pipeline
The lead candidate, ANAVEX 2-73 (blarcamesine), is being studied for Alzheimer’s disease, Parkinson’s disease dementia (PDD), and Rett syndrome, using a precision-medicine approach based on genomic biomarkers. ANAVEX 3-71 began a Phase 1 study in 2020; other candidates remain preclinical. The company had 20 full-time employees.
- The Alzheimer’s Phase 2b/3 trial was enrolling approximately 450 patients, with sites expanded internationally during FY2020.
- Rett syndrome programs included the AVATAR Phase 2 study and the EXCELLENCE pediatric Phase 2/3 study, both ongoing at fiscal year-end. The filing also reports that the U.S. Phase 2 Rett study completed in December 2020, after year-end, with company-reported positive secondary endpoint results.
- The PDD Phase 2 trial completed in October 2020, after year-end. The company reported favorable safety and statistically significant, dose-dependent improvements on a computerized cognitive assessment; investors should treat these as company-reported results pending review of full trial data.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $25.2 million | $22.3 million |
| General and administrative expense | $5.9 million | $6.8 million |
| Total operating expenses | $31.1 million | $29.1 million |
| Other income, net | $4.8 million | $2.9 million |
| Net loss | $26.3 million | $26.3 million |
| Basic and diluted loss per share | $0.45 | $0.54 |
| Cash and cash equivalents at September 30 | $29.2 million | $22.2 million |
| Net cash used in operating activities | $21.3 million | $18.5 million |
| Net cash provided by financing activities | $28.4 million | $17.8 million |
| Working capital | $27.2 million | $20.3 million |
Operating expenses rose 6.9%, principally because R&D spending increased 13.3% as clinical programs expanded. Higher R&D incentive income, including Australian tax-credit income, helped offset expenses. The company reported no debt; its $7.3 million of liabilities were current. No operating margin is meaningful because the company has no revenue. Accumulated deficit was approximately $159.7 million.
Funding, outlook, and risks
FY2020 operations were funded chiefly through equity issuance: approximately 9.4 million shares were issued for gross proceeds of $28.8 million under the Lincoln Park purchase agreement and an at-the-market sales agreement. At September 30, approximately $24.1 million remained available under the Lincoln Park agreement and $42.5 million under the sales agreement, subject to contractual limits and market conditions. Management stated that existing cash and financial commitments were expected to cover cash commitments for more than two years after the financial statements were issued. This is not assurance of profitability or of access to all committed financing.
- Management expects negative cash flows for the foreseeable future and cannot predict when, if ever, the company will become profitable. Further capital may be needed; inability to raise it could delay, reduce, or end development programs.
- COVID-19 temporarily slowed activity in some trial locations. Management said trials continued largely uninterrupted and the pandemic did not materially affect FY2020 results, but future effects were uncertain.
- Material risks include clinical failure or safety issues, regulatory delays or rejection, trial enrollment and execution, reliance on third-party researchers and manufacturers, competition, patent and licensing challenges, and potential shareholder dilution from future equity sales.
- ANAVEX 2-73 received FDA Fast Track designation for Rett syndrome; the filing cautions that such designation does not guarantee faster review or approval. Orphan and rare-pediatric designations likewise do not establish efficacy or approval.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements. Its auditor gave an unqualified opinion on the financial statements; management concluded disclosure controls and internal control over financial reporting were effective. The auditor was not engaged to opine on internal-control effectiveness.
Most important facts for investors to verify
- Review complete protocols, prespecified endpoints, statistical analyses, safety findings, and subsequent regulatory feedback for the Alzheimer’s, PDD, and Rett studies—especially the results disclosed after fiscal year-end.
- Assess the cash runway using actual spending, timing and collection of incentive receivables, trial costs, and the availability and terms of remaining equity-funding capacity.
- Track share-count growth, outstanding options and warrants, and potential dilution from the Lincoln Park and at-the-market programs.
- Confirm that management’s stated cash runway and clinical timelines remain current, particularly given pandemic-related uncertainty and the company’s continuing losses.